Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Unknown 2Recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 14OTHER 7OTHER_GOV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 11Breast Neoplasms 11Neoplasm Metastasis 10Carcinoma, Renal Cell 8Carcinoma, Merkel Cell 8Neoplasms 7Colorectal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4Leukemia, Myeloid, Acute 4Urethral Neoplasms 3Ureteral Neoplasms 3Skin Neoplasms 3Prostatic Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Carcinoma, Neuroendocrine 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Sarcoma 2Penile Neoplasms 2Pancreatic Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm, Residual 2Mesothelioma, Malignant 2

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
OTHER × Neoplasms × avelumab × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

University of California, San Diego

Phase 1 Active not recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03050554 2024-08-09

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

University of California, San Diego

Phase 1/2 Terminated
2 enrolled 6 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Johannes Gutenberg University Mainz

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed
60 enrolled
EndocrineNET

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03812796 2019-02-05

EMERGE

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
75 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡